Foghorn Therapeutics (FHTX) to Release Quarterly Earnings on Thursday

Foghorn Therapeutics (NASDAQ:FHTX) is anticipated to release its earnings data before the market opens on Thursday, March 6th. Analysts expect Foghorn Therapeutics to post earnings of ($0.43) per share and revenue of $8.56 million for the quarter.

Foghorn Therapeutics Trading Up 1.6 %

NASDAQ FHTX opened at $4.39 on Wednesday. The firm has a market cap of $244.14 million, a price-to-earnings ratio of -2.29 and a beta of 3.18. The company has a 50 day moving average of $4.74 and a 200-day moving average of $6.77. Foghorn Therapeutics has a 1-year low of $3.86 and a 1-year high of $10.25.

Analyst Ratings Changes

A number of analysts recently weighed in on FHTX shares. HC Wainwright reissued a “buy” rating and issued a $13.00 price target (down previously from $20.00) on shares of Foghorn Therapeutics in a report on Tuesday, December 17th. B. Riley started coverage on shares of Foghorn Therapeutics in a report on Thursday, January 30th. They issued a “buy” rating and a $10.00 price target for the company. Finally, Jefferies Financial Group lowered their price target on shares of Foghorn Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a report on Monday, December 16th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $13.17.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.